RxDoctor Payments Data

Ralitza Gavrilova, MD

Clinical Genetics (M.D.) · Rochester, MNNPI 1558333005

Payments from drug & device makers

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$1,075,503in research payments, 2019–2025

Across 38 payments — averaging $28,303 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astellas Pharma Inc$951K
  • Genentech, Inc.$124K

How this compares

Too few clinical genetics (m.d.) providers in Minnesotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$8,267
Medicare patients
58
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex (4 Pack)Interferon Beta-1a11$89,704

Paid to pharmacies, not to this prescriber.

Other clinical genetics (m.d.) in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →